-- Robert Preidt
MONDAY, Oct. 28 (HealthDay News) -- Researchers report they have
pinpointed 11 new genes linked to late-onset Alzheimer's disease,
doubling the number of potential targets for drug development.
The international team of scientists analyzed genetic data from
more than 25,500 Alzheimer's patients and more than 49,000 people
without the memory-robbing disease in 15 countries.
Along with adding 11 new genes to those already known to be
associated with Alzheimer's, the researchers identified 13 other
genes that require further investigation, according to the study
published Oct. 27 in the journal
The findings provide a wider view of the genetic factors that
contribute to Alzheimer's and increases the understanding of the
disease to new areas. This includes the immune system, where a
genetic overlap with other neurodegenerative diseases, including
multiple sclerosis and Parkinson's, was identified.
"The discovery of [new] pathways is very encouraging, considering the limited success of Alzheimer's disease drugs tested so far," Margaret Pericak-Vance, director of the Institute for Human Genomics at the University of Miami Miller School of Medicine, said in a school news release.
"Our findings bring us closer toward identifying new drug targets for Alzheimer's and other neurodegenerative diseases. We'll continue to expand and analyze our data set with this incredible group so that we can better understand the genetic influences on this devastating disease, and find new medical and therapeutic interventions," said Pericak-Vance, co-leader of the analysis teams for the American Alzheimer's Disease Genetics Consortium that worked on the study.
Several of the 11 genes identified in the study confirm known
biological pathways of Alzheimer's disease. One of the more
significant new genes was found in a part of the genome that plays
a role in the immune system and inflammatory response. This
suggests that diseases where abnormal proteins accumulate in the
brain -- Alzheimer's, Parkinson's and multiple sclerosis -- may
have a common mechanism and possibly a common drug target.
The U.S. National Institute of Neurological Disorders and Stroke
has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.